Literature DB >> 27408415

Resolution of Serologic Problems Due to Cold Agglutinins in Chronic Lymphocytic Leukemia.

Rizwan Javed1, Suvro Sankha Datta1, Sabita Basu1, Anupam Chakrapani2.   

Abstract

INTRODUCTION: Autoimmune hemolytic anemia can be classified depending on presence of warm, cold or mixed type of autoantibodies that are directed against antigens on the red blood cell surface. Here we report a case of pathological cold agglutinin disease which was eventually detected due to blood group discrepancy. CASE DETAILS: A request was sent to the blood bank for two units of packed red cells in a diagnosed case of CLL which showed type IV discrepancy during blood grouping.The discrepancy was subsequently resolved after warm saline washing of red cells along with repetition of reverse grouping with pre-warmed serum. The direct antiglobulin test was positive and revealed autoanibodies against C3b/C3d only. Indirect antiglobulin test was performed with 3-cell panel in a polyspecific gel card (IgG+C3d) showed a pan-reactive pattern along with a positive autocontrol. Subsequently a cold agglutinin titration was performed and titers of 1024 at 4 °C; titer of 2 at room temperature were detected. Dithiothreitol (DTT) treatment of serum was undertaken and IgM type of autoantibody was detected in this case confirming a case of secondary cold agglutinin disease in this patient. Two units of red cells were transfused to this patient after successfully performing cross-match with pre-warmed serum. It was advised from the blood bank that the blood should be transfused slowly through a blood-warmer and patient should be kept in warm condition to avoid in-vivo hemolysis due to high titer of cold agglutinin. The transfusion was uneventful and patient is on regular follow-up till now.
CONCLUSION: Thus we concluded that serological discrepancies observed in blood bank can successfully guide the bedside transfusion protocol in case of cold agglutinin disease.

Entities:  

Keywords:  CLL; Cold agglutinins; Serologic problems; Titer

Year:  2016        PMID: 27408415      PMCID: PMC4925551          DOI: 10.1007/s12288-016-0644-4

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  10 in total

1.  Cold agglutinin disease.

Authors:  Morie A Gertz
Journal:  Haematologica       Date:  2006-04       Impact factor: 9.941

Review 2.  Cold agglutinin disease.

Authors:  Paul L Swiecicki; Livia T Hegerova; Morie A Gertz
Journal:  Blood       Date:  2013-06-11       Impact factor: 22.113

Review 3.  The cold hemagglutinin disease.

Authors:  H Schubothe
Journal:  Semin Hematol       Date:  1966-01       Impact factor: 3.851

Review 4.  How I treat autoimmune hemolytic anemias in adults.

Authors:  Klaus Lechner; Ulrich Jäger
Journal:  Blood       Date:  2010-06-14       Impact factor: 22.113

Review 5.  Autoimmune hemolytic anemia.

Authors:  Bradley C Gehrs; Richard C Friedberg
Journal:  Am J Hematol       Date:  2002-04       Impact factor: 10.047

Review 6.  How I manage cold agglutinin disease.

Authors:  Sigbjørn Berentsen
Journal:  Br J Haematol       Date:  2011-03-08       Impact factor: 6.998

7.  Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.

Authors:  Sigbjørn Berentsen; Elling Ulvestad; Ruth Langholm; Klaus Beiske; Henrik Hjorth-Hansen; Waleed Ghanima; Jon Hjalmar Sørbø; Geir E Tjønnfjord
Journal:  Haematologica       Date:  2006-04       Impact factor: 9.941

8.  Human monoclonal macroglobulins with antibody activity.

Authors:  Marvin J Stone; Yolonda G McElroy; Alan Pestronk; Janet L Reynolds; Joseph T Newman; Alex W Tong
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

Review 9.  Cold antibody autoimmune hemolytic anemias.

Authors:  Lawrence D Petz
Journal:  Blood Rev       Date:  2007-09-27       Impact factor: 8.250

Review 10.  Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy.

Authors:  Sigbjørn Berentsen; Klaus Beiske; Geir E Tjønnfjord
Journal:  Hematology       Date:  2007-10       Impact factor: 2.269

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.